Health Economic Evaluation of Tecentriq in Combination with bevacizumab, paclitaxel and carboplatin
TLV has in collaboration with the Finnish Medicines Agency (Fimea) and the Norwegian Medicines Agency (NoMA) produced a health economic evaluation of Tecentriq (atezolizumab) in combination with the substances bevacizumab, paklitaxel och karboplatin against metastatic non-squamous non-small cell lung cancer (NSCLC). Focus of the evaluation has been on patients with so called EGFR-mutated or ALK-positive NSCLC after failure of appropriate targeted therapies.
The efficacy of Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel and carboplatin has been evaluated in a trial named IMPOWER-150. In the patient group with activating EGFR mutations or ALK fusions, the data suggests that there is a clinical benefit when atezolizumab is added to bevacizumab and chemotherapy. However, there are significant uncertainties due to the low number of patients in the trial.
The company presents a cost-effectiveness model for the Tecentriq combination compared to either carboplatin in combination with vinorelbin or cisplatin in combination with pemetrexed based on the patient population in IMPOWER-150. The health economic results are dependent on negotiated prices for Tecentriq and Avastin (bevacizumab).
The evaluation of Tecentriq in combination with bevacizumab, paclitaxel and carboplatin is part of a Nordic collaboration
TLV has together with the agencies in Finland and Norway within FINOSE, written a joint assessment report for the Tecentriq combination.
FINOSE is a collaboration between the HTA agencies Fimea (Finland), Norwegian Medicines Agency (Norway) and TLV (Sweden). The co-operation consists in the three agencies writing joint assessment reports for pharmaceutical products, that contain both relative clinical and health economic assessments. This is the second joint assessment report within the FINOSE collaboration.
Publicerad 27 juni 2019